<code id='52ED03C393'></code><style id='52ED03C393'></style>
      • <acronym id='52ED03C393'></acronym>
      <center id='52ED03C393'><center id='52ED03C393'><tfoot id='52ED03C393'></tfoot></center><abbr id='52ED03C393'><dir id='52ED03C393'><tfoot id='52ED03C393'></tfoot><noframes id='52ED03C393'>
      • <optgroup id='52ED03C393'><strike id='52ED03C393'><sup id='52ED03C393'></sup></strike><code id='52ED03C393'></code></optgroup>
        5. <b id='52ED03C393'><label id='52ED03C393'><select id='52ED03C393'><dt id='52ED03C393'><span id='52ED03C393'></span></dt></select></label></b><u id='52ED03C393'></u>
          <i id='52ED03C393'><strike id='52ED03C393'><tt id='52ED03C393'><pre id='52ED03C393'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-29 12:01:23 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：25652
                                  
                                    
          
                                   
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Burning questions about Delta and the next phase of the Covid pandemic
                                
                            
          Next article：  
                                      
                                          Moonlake's readout produced a cash windfall. Risks remain
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles